|Day Low/High||93.37 / 94.87|
|52 Wk Low/High||74.97 / 96.31|
Array is partnering with AstraZeneca and Novartis on a number of cancer drugs with trials soon getting underway that could transform the company by year end.
When investing beyond your own shores, choose value over growth.
Let's take a peek at overnight and early-morning price action in the major asset classes. Exit light Enter night Take my hand We're off to never never land. -- Metallica, "Enter Sandman" Let's take a peek at overnight and early-morning price action ...
Two domestic exploration and production names that scream 'buy me' are Devon and Southwestern.
A look at the day's most searched trends on the Web, including UBS after the Swiss bank posted a worse-than-expected second-quarter profit due to losses it incurred from the Facebook initial public offering.
IRM has been trading in a declining triangle pattern since July. Technical indications of NVS are also positive.
A look at the day's most searched trends on the Web, including Amgen after the passing of its founding CEO.
Plenty of stocks are exhibiting these formations -- here's how to tell where they'll go from here.
Indicators pointed to a not-so-super Tuesday, as international growth concerns weighed on U.S futures.
Futures point to a mixed open ahead of several economic reports and slumping earnings from JPMorgan.
Despite worries of a rising franc, there are Swiss companies that check all the boxes for your portfolio.
A relief rally failed to materialize, and Wall Street futures are pointing to a lower open.